Following the approval of atezolizumab (anti-PD-L1) plus bevacizumab, an anti-vascular endothelial growth factor A (anti-VEGF-A), as first-line therapy for unresectable HCC in 2020, treatment with ICIs has generated growing interest for the treatment of HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.